Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Electronic Labeling Study By GAO Yields “No Consensus,” Avoids Cost Issue

This article was originally published in The Pink Sheet Daily

Executive Summary

In study mandated by FDASIA, GAO says there are advantages and disadvantages to switching to an electronic-only system for distributing drug label information, but offers no conclusions.


Related Content

Will Antimicrobial Breakpoint Changes Signal Shift To Online Labeling Updates?
Priority Review Vouchers, FDA Funding Win In Omnibus Budget Deal
Electronic Prescribing Information: Proposed Rule May Not Completely Eliminate Paper
FDA’s Spring Regulatory Agenda Includes 17 Rx Drug-Related Rules
FDA Labeling Change Rule Is Most Prominent Item On Agency’s To-Do List
FDASIA Study Mandates Focus On Performance, But Could Slow Reviews
FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts